United States Drug Manufacturers - General news

18:18 20 Jul 2026

Benzinga Macro sensitivity Main company 🇺🇸 United States

Pfizer Suspends Popular Menopause Cream in India

Pfizer has temporarily suspended the distribution of its Premarin vaginal cream in India due to unspecified supply chain difficulties, significantly reducing estrogen therapy options for women. This move impacts over 620,000 units sold annually and leaves few alternatives for genitourinary syndrome of menopause in …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

17:40 20 Jul 2026

Reuters Regulatory and legal Main company 🇺🇸 United States

Aspen Pharmacare wins Canada approval for generic Ozempic after Novo patent expiry

South Africa's Aspen Pharmacare has received Canadian regulatory approval for Aspen-Semaglutide, a generic version of Novo Nordisk's Ozempic, for type 2 diabetes management. The launch timing in Canada depends on the availability of semaglutide API from India's Dr. Reddy's Laboratories, which has faced supply …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

16:39 20 Jul 2026

FXEmpire Earnings Main company 🇺🇸 United States

Novartis Earnings Preview: Can New Medicines Offset Generic Pressure and Growing U.S. Pricing Risks?

Novartis is entering its Q2 earnings call facing significant pressure from generic competition and U.S. drug pricing reforms, having already experienced weaker Q1 revenues. Investors will closely watch whether new growth drivers like Kisqali, Pluvicto, and Kesimpta can continue to offset losses from patent …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

15:41 20 Jul 2026

Stock Titan Market update Main company 🇺🇸 United States

EMA reviews GSK (NYSE: GSK) plan for 1-dose Bexsero meningitis B booster

GSK has announced that the European Medicines Agency (EMA) has accepted its submission to update the label for Bexsero to include a single-dose booster for individuals aged 10 years and older who were previously vaccinated. This proposed booster aims to help reduce the burden …

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

15:38 20 Jul 2026

KHOU Market update Main company 🇺🇸 United States

Eli Lilly moves forward with $6.5B manufacturing plant in Houston

This article reports that pharmaceutical giant Eli Lilly is proceeding with its plans to build a $6.5 billion manufacturing plant in Houston. The plant is expected to significantly boost the company's production capabilities. Further details about the plant's production focus or job creation were …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

15:33 20 Jul 2026

Pharmaceutical Executive Market update Main company 🇺🇸 United States

Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory

Bristol Myers Squibb (BMS) is significantly expanding its collaboration with Nvidia by deploying DGX SuperPOD with Vera Rubin NVL72 systems, creating what it claims is the most powerful AI computing infrastructure in life sciences. This aims to accelerate drug discovery and development across various …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

15:07 20 Jul 2026

finance.yahoo.com Market update Main company 🇺🇸 United States

Novo Nordisk (CPSE:NOVO B) Launches Kyinsu In China Through Fangzhou Internet Hospital

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Novo Nordisk (CPSE:NOVO B) and Fangzhou have launched Kyinsu®, the world's first once weekly basal insulin/GLP-1 RA combination therapy, in China. The product is being introduced through …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

14:51 20 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Does EU Approval of Wegovy Pill Change NVO's Competitive Story?

Novo Nordisk NVO received a meaningful commercial boost last week after the European Commission approved the oral version of Wegovy (semaglutide 25 mg) for adults with obesity and at least one weight-related comorbidity. The approval expands the company's obesity franchise across Europe, making Wegovy …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

14:40 20 Jul 2026

Market source Analyst action Main company 🇺🇸 United States

Citi lifts Novo Nordisk target on strong GLP-1 pill launch

Citi has raised its price target for Novo Nordisk (NYSE:NVO) to DKK330, citing strong launch performance of its GLP-1 pill, Wegovy. The broker increased sales and operating income estimates for 2026-2030 and expects the company to raise its full-year guidance, despite competition from Eli …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

14:00 20 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

14:00 20 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this drugmaker have returned -0.6% over the past …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

13:38 20 Jul 2026

Ad-hoc-news.de Earnings Main company 🇺🇸 United States

Merck stock trades steadily as Keytruda growth underpins guidance

Merck & Co.'s stock performance is strongly supported by the growing revenue from its flagship immuno-oncology therapy, Keytruda, and the company's consistent guidance. The pharmaceutical giant focuses on oncology and vaccines, with sustained R&D investment and a strong pipeline crucial for long-term value, especially …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

13:22 20 Jul 2026

Seeking Alpha Market update Main company 🇺🇸 United States

Bristol Myers boosts AI capacity with expanded use of Nvidia systems

Bristol Myers Squibb (BMY) has expanded its artificial intelligence capabilities by implementing Nvidia's (NVDA) DGX SuperPOD with DGX Vera Rubin NVL72 systems. This move is expected to enhance the drugmaker's operations, leveraging Nvidia's supercomputing infrastructure.

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

13:17 20 Jul 2026

Pulse 2.0 Market update Main company 🇺🇸 United States

Bristol Myers Squibb Deploys NVIDIA Vera Rubin AI Factory To Accelerate Drug Discovery

Bristol Myers Squibb is expanding its use of artificial intelligence for drug discovery by deploying a second NVIDIA DGX SuperPOD, an "AI factory" built on NVIDIA DGX Vera Rubin NVL72 systems. This initiative aims to provide all scientists with access to a unified AI …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

13:17 20 Jul 2026

finance.yahoo.com Market update Main company 🇺🇸 United States

Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form …

AZN main company

Sharemaestro market context Price below Trend Line 52 weeks -1.4%

13:11 20 Jul 2026

Bloomberg.com Market update Main company 🇺🇸 United States

Bristol Partners With Nvidia on AI Factory for Drug Development

Bristol Myers Squibb Co. is expanding its partnership with Nvidia Corp. to enhance the computing power of its AI factory, aiming to accelerate the development of new medicines. This collaboration is part of a broader trend where the chipmaker partners with the pharma industry …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

13:06 20 Jul 2026

MarketWatch Market update Main company 🇺🇸 United States

GSK falls Monday, underperforms market

Shares of GSK PLC (GSK) fell on Monday, sliding 1.80% to £18.82, underperforming the broader market as the FTSE 100 Index also declined. The company's stock closed significantly below its 52-week high.

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

13:00 20 Jul 2026

finance.yahoo.com Regulatory and legal Main company 🇺🇸 United States

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

July 2026 CHMP meeting commences today, prior to FDA inspection classification for Catalent Indiana LLC (part of Novo Nordisk) fill-finish facility Apitegromab CHMP Opinion expected following resolution of Catalent Indiana classification status or inclusion of second fill-finish facility in MAA CAMBRIDGE, Mass., July 20, …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

12:53 20 Jul 2026

EIN News Market update Provider-linked mention 🇺🇸 United States

Cancer Therapy Market is Going to Boom: New Report Reveals Massive Growth Potential 2026-2033 | Sanofi, Bayer AG

A new report by Coherent Market Insights forecasts significant growth for the cancer therapy market, projecting it to reach USD 605.35 billion by 2033 from USD 260.52 billion in 2026. The study provides an in-depth analysis of market dynamics, segmentation, competitive landscape, and regional …

SNY mentioned

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

12:26 20 Jul 2026

Crypto Briefing Market update Main company 🇺🇸 United States

Nvidia partners with Bristol-Myers Squibb to build AI supercomputer for drug discovery

Bristol-Myers Squibb (BMS) has partnered with Nvidia to establish a dedicated AI supercomputer for drug discovery, leveraging Nvidia's DGX SuperPOD technology. This "AI Center of Excellence" has been operational since March 2024, focusing on oncology research and predicting patient outcomes in immuno-oncology, and has …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

12:02 20 Jul 2026

Reuters Deals and strategy Main company 🇺🇸 United States

Bristol Myers buys Nvidia's latest AI computing system for drug research

Bristol Myers Squibb announced its acquisition of Nvidia's cutting-edge DGX SuperPOD computing system, based on its new Vera Rubin architecture, to enhance AI-driven drug discovery and development. The pharmaceutical company aims to accelerate the identification of drug targets and improve success rates in clinical …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

12:02 20 Jul 2026

NVIDIA Blog Market update Main company 🇺🇸 United States

Bristol Myers Squibb Building Life Science Industry’s Most Advanced AI Factory on NVIDIA Vera Rubin

Bristol Myers Squibb (BMS) is significantly expanding its AI capabilities by deploying a second NVIDIA DGX SuperPOD, specifically built on eight DGX Vera Rubin NVL72 systems, to create the life science industry's most advanced AI factory. This initiative aims to democratize AI access for …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

11:20 20 Jul 2026

DirectorsTalk Interviews Earnings Main company 🇺🇸 United States

Grifols, S.A. (GRFS) Stock Analysis: Unlocking Potential With A 49.45% Upside

Grifols, S.A. (NASDAQ: GRFS) is presented as an intriguing investment opportunity in the healthcare sector, particularly for its potential upside of 49.45% based on an average target price. Despite a recent revenue decline, the company boasts a strong market position in plasma-derived medicines, an …

GRFS main company

Sharemaestro market context Price below Trend Line 52 weeks -23.4%

11:18 20 Jul 2026

DirectorsTalk Interviews Earnings Main company 🇺🇸 United States

Biogen Inc. (BIIB) Stock Analysis: Exploring a 9.86% Potential Upside Amid Robust Therapeutic Portfolio

Biogen Inc. (BIIB) presents a compelling investment opportunity in the healthcare sector, backed by a robust therapeutic portfolio in neurological conditions. With a market capitalization of $30.41 billion and a current trading price of $205.99, analysts project a potential upside of 9.86%, targeting $226.29. …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

11:14 20 Jul 2026

Crain's Chicago Business Regulatory and legal Main company 🇺🇸 United States

AbbVie’s Allergan gets European nod for its Botox-lite treatment

AbbVie's Allergan has received European approval for its new "Botox-lite" treatment. This development marks a significant step for Allergan in expanding its cosmetic product offerings within the European market. The article is from Crain's Chicago Business, indicating local relevance for the company's operations.

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

11:08 20 Jul 2026

Axios Market update Main company 🇺🇸 United States

Axios C-Suite: Pfizer CEO on biotech's China warning

Pfizer CEO Albert Bourla addresses the growing influence of China in the biotech industry, noting its rapid rise as a scientific superpower due to lower costs and faster development. He advises other CEOs to confront both the threats and opportunities China presents, emphasizing a …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

11:02 20 Jul 2026

DirectorsTalk Interviews Earnings Main company 🇺🇸 United States

AbbVie Inc. (ABBV): Investor Outlook Highlights Robust Revenue Growth and Dividend Appeal

AbbVie Inc. (ABBV) continues to attract investor attention with its robust revenue growth of 12.40% and a market capitalization of $449.63 billion. While its dividend yield of 2.72% is appealing, its high payout ratio of 325.98% warrants careful monitoring. Analysts remain largely positive, with …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

10:50 20 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

KBC Group NV Sells 319,966 Shares of Amgen Inc. $AMGN

KBC Group NV significantly reduced its stake in Amgen Inc. by 55.9% in the first quarter, selling 319,966 shares and retaining 252,179 shares valued at approximately $88.7 million. Amgen reported strong quarterly earnings, beating analyst estimates, and raised its FY 2026 EPS guidance, yet …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

10:09 20 Jul 2026

Crain's New York Market update Main company 🇺🇸 United States

Pfizer site developer’s complex conversion technique draws attention after collapse scare

Nathan Berman's complex conversion technique at a former Pfizer site has come under scrutiny after a collapse scare. Falling debris from a 37-story Midtown Manhattan building undergoing office-to-residential conversion led to building evacuations and street closures. The incident draws attention to the challenging engineering …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

10:08 20 Jul 2026

DirectorsTalk Interviews Earnings Main company 🇺🇸 United States

Pfizer Inc. (PFE) Stock Analysis: Evaluating a 14.92% Potential Upside Amidst Strong Dividend Yield

This article analyzes Pfizer Inc. (PFE), highlighting its potential 14.92% upside and strong 6.87% dividend yield. While performance metrics and strategic collaborations suggest growth, the high 131.30% payout ratio raises questions about dividend sustainability. Analyst sentiment is mixed, indicating cautious optimism, while technical indicators …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

09:52 20 Jul 2026

Semafor Market update Main company 🇺🇸 United States

Novo Nordisk launches cheaper Ozempic in South Africa

Novo Nordisk has introduced a lower-cost version of its weight-loss drug, Ozempic, in South Africa, aiming to combat counterfeit products. This move follows a court victory against local pharmacies making unauthorized copies. South Africa has the highest adult obesity rate in Africa, and the …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

09:38 20 Jul 2026

24/7 Wall St. Earnings Main company 🇺🇸 United States

Why Johnson & Johnson Is a Stock You Can Own Forever

Johnson & Johnson (JNJ) is presented as a stock ideal for long-term investors due to its strong balance sheet, 64-year dividend growth streak, and diversified healthcare business spanning pharmaceuticals and medical devices. The company's durability is evidenced by its consistent revenue growth across six …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

09:08 20 Jul 2026

The Globe and Mail Earnings Main company 🇺🇸 United States

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?

Pfizer is actively developing several weight management drugs and recently acquired Metsera, significantly boosting its pipeline in this growing market. While Pfizer has promising candidates, particularly MET-097i with potential for monthly dosing, it faces strong competition from market leaders like Eli Lilly and Novo …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

09:07 20 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Boston Common Asset Management LLC Lowers Stake in Amgen Inc. $AMGN

Boston Common Asset Management LLC decreased its stake in Amgen Inc. by 10.4% in the first quarter, selling 3,458 shares and leaving its holding valued at $10.4 million. Despite this, Amgen reported strong first-quarter results, beating EPS and revenue estimates, and raised its FY …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

08:23 20 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

AlTi Global Inc. Cuts Stock Position in Amgen Inc. $AMGN

AlTi Global Inc. significantly reduced its stake in Amgen Inc. by 31.7% in the first quarter, selling 9,833 shares and valuing its remaining 21,159 shares at $7.445 million. While institutional investors collectively own 76.50% of Amgen, several other hedge funds either increased or decreased …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

07:05 20 Jul 2026

Market source Earnings Main company 🇺🇸 United States

Novartis pipeline faces critical test as upcoming trial results underpin growth outlook

Novartis is facing a critical period as upcoming trial results for three late-stage medicines will determine its long-term growth. These trials for pelacarsen, remibrutinib, and del-desiran are crucial for supporting the company's premium market valuation and offsetting future patent expirations, with analysts projecting these …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%